Subcutaneous versus Intravenous Administration of Bortezomib in Multiple Myeloma
CME INFORMATION

OVERVIEW OF ACTIVITY

The annual American Society of Hematology (ASH) meeting is unmatched in its importance with regard to advancements in hematologic cancer and related disorders. It is targeted by many members of the clinical research community as the optimal forum in which to unveil new clinical data. This creates an environment each year in which published results from a plethora of ongoing clinical trials lead to the emergence of many new therapeutic agents and changes in the indications for existing treatments across virtually all malignant and benign hematologic disorders. As online access to posters and plenary presentations is not currently available, a need exists for additional resources to distill the information presented at the ASH annual meeting for those clinicians unable to attend but desiring to remain up to date on the new data released there. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets from the latest ASH meeting, including expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists and other cancer clinicians in the formulation of optimal clinical management strategies for hematologic cancer.

LEARNING OBJECTIVES

- Compare and contrast the efficacy and safety outcomes with subcutaneous versus intravenous bortezomib administration in multiple myeloma.
- Counsel patients with multiple myeloma about the known benefits and risks of bortezomib when administered subcutaneously and intravenously.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains slides and edited commentary. To receive credit, the participant should review the slide presentation, read the commentary and complete the Educational Assessment and Credit Form located at CME.ResearchToPractice.com.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Rafael Fonseca, MD
Consultant, Professor of Medicine
Mayo Clinic Arizona
Deputy Director, Mayo Clinic Cancer Center
Scottsdale, Arizona

Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genzyme Corporation, Medtronic Inc, Otsuka Pharmaceutical Co Ltd; Paid Research: Celgene Corporation, Onyx Pharmaceuticals Inc.

EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium — The Takeda Oncology Company, Mundipharma International Limited, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This program is supported by educational grants from Allos Therapeutics, Celgene Corporation, Millennium — The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc and Seattle Genetics.

Last review date: March 2011
Expiration date: March 2012
Click here for papers on proteasome inhibitors and IMiDs in multiple myeloma

In the last issue of our San Antonio-focused edition of this series, we opined about the lack of recent research progress in breast cancer and looked to a tumor occurring at one tenth the frequency for inspiration and hope. Multiple myeloma affects approximately 20,000 new patients in the US annually and for a long time was a disease stuck for new therapeutic options. However, fairly recently two classes of treatments have stormed onto the scene — immunomodulatory agents (IMiDs) and proteasome inhibitors — making myeloma perhaps the fastest moving and most dynamic area in oncology.

It’s difficult to figure out exactly what led to this encouraging state of affairs, but those in the middle of it all claim that an effective partnership between academia, industry and unusually active advocacy groups made it happen. One might also consider that perhaps there was a unique and fortunate tumor biopharmacology at work here. Regardless of the source of this important progress, currently, lenalidomide, bortezomib and to a lesser extent thalidomide are helping patients with myeloma live longer and feel better. Perhaps even more importantly, two exciting but not yet approved agents — carfilzomib and pomalidomide — seem poised to further transform the classic paradigms of this enigmatic disease. Several related ASH data sets provide a glimpse of what the future may hold for these unique classes of agents:

1. **Subcutaneous bortezomib**

A large (n = 222) international Phase III study demonstrated similar efficacy but markedly less neurotoxicity when SC bortezomib was compared to IV administration in the refractory setting. These intriguing findings suggest that higher peak drug levels occurring with IV treatment may correlate with neuronal damage and that the SC approach may offer obvious patient care advantages. Investigators are very quickly attempting to further validate this interesting concept. Another important clinical research avenue with bortezomib as presented by Antonio Palumbo and others is weekly dosing of the agent, which seems to be equally efficacious and much less neurotoxic.

2. **Pomalidomide**

Two more Phase II studies of this fascinating and well-tolerated IMiD combined with dexamethasone demonstrated substantial antitumor effect in almost half of the trial participants, all of whom were considered refractory to both bortezomib and lenalidomide. Clinicians seem ready to use this drug now.
3. **Carfilzomib**

Again, significant activity was seen in later-line treatment in two separate Phase II studies, with minimal neurotoxicity, including a lack of worsening of this challenging adverse effect in patients with baseline peripheral neuropathy. A current compelling Phase III study is randomly assigning patients to either CRD or Rd in the search for the “R-CHOP” of myeloma. As with pomalidomide, oncologists again seem ready and interested in utilizing this agent.

Next up on our final ASH 5-Minute Journal Club: Papers on MDS, AML and my personal favorite current topic in oncology, AP.

Neil Love, MD

Research To Practice
Miami, Florida
Subcutaneous versus Intravenous Administration of Bortezomib in Multiple Myeloma

Presentation discussed in this issue


Slides from a presentation at ASH 2010 and transcribed comments from a recent interview with Rafael Fonseca, MD (12/22/10)
**Phase III Multicenter Trial Schema**

**Eligibility**
- Relapsed multiple myeloma
- 1-3 prior lines of therapy
- No prior treatment with bortezomib

**Primary Endpoint**
Overall response rate after 4 cycles of therapy

**Subcutaneous (SC)**
- Bortezomib 1.3 mg/m²
- Days 1, 4, 8 and 11
  - (n = 148)

**Intravenous (IV)**
- Bortezomib 1.3 mg/m²
- Days 1, 4, 8 and 11
  - (n = 74)

Eight 21-day cycles (plus 2 cycles if unconfirmed or delayed PR)
If sPR after 4 cycles, 20 mg Dex on days 1, 2, 4, 5, 8, 9, 11, 12 added in the next 4 cycles


---

**Treatment Exposure**

<table>
<thead>
<tr>
<th></th>
<th>Bortezomib SC (n = 147)*</th>
<th>Bortezomib IV (n = 74)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Cycles (Median)</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Time on Study Drug (Median)</td>
<td>22.57 weeks</td>
<td>22.57 weeks</td>
</tr>
<tr>
<td>Cumulative Bortezomib Dose (Median)</td>
<td>33.76 mg/m²</td>
<td>31.46 mg/m²</td>
</tr>
<tr>
<td>Patients Receiving Dexamethasone</td>
<td>56%</td>
<td>53%</td>
</tr>
</tbody>
</table>

* Data shown for safety population. One patient in the SC arm was not treated.

## Clinical Responses After Four Cycles

<table>
<thead>
<tr>
<th></th>
<th>Bortezomib SC (n = 145)</th>
<th>Bortezomib IV (n = 73)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall Response Rate⁴</td>
<td>42%</td>
<td>42%</td>
</tr>
<tr>
<td>Complete Response (CR)</td>
<td>6%</td>
<td>8%</td>
</tr>
<tr>
<td>Partial Response (PR)</td>
<td>36%</td>
<td>34%</td>
</tr>
<tr>
<td>≥Very Good PR (VGPR)</td>
<td>17%</td>
<td>16%</td>
</tr>
</tbody>
</table>

⁴ Relative risk of overall response rate is 0.99 with 95% confidence interval of 0.71-1.37


## Additional Efficacy Outcomes

<table>
<thead>
<tr>
<th>In Responding Patients</th>
<th>Bortezomib SC (n = 76)</th>
<th>Bortezomib IV (n = 38)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time to First Response (Median)</td>
<td>1.4 mos</td>
<td>1.4 mos</td>
</tr>
<tr>
<td>Time to Best Response (Median)</td>
<td>1.6 mos</td>
<td>1.5 mos</td>
</tr>
<tr>
<td>Duration of Response (Median)</td>
<td>9.7 mos</td>
<td>8.8 mos</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Intent-to-Treat Population</th>
<th>Bortezomib SC (n = 148)</th>
<th>Bortezomib IV (n = 74)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time to Disease Progression (Median)</td>
<td>10.4 mos</td>
<td>9.4 mos</td>
</tr>
<tr>
<td>One-Year Survival Rate</td>
<td>72.6%</td>
<td>76.7%</td>
</tr>
</tbody>
</table>

Select Adverse Events

<table>
<thead>
<tr>
<th></th>
<th>Bortezomib SC (n = 147)</th>
<th>Bortezomib IV (n = 74)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade ≥3 Adverse Events</td>
<td>57%</td>
<td>70%</td>
<td>—</td>
</tr>
<tr>
<td>Grade 3/4 Anemia</td>
<td>14%</td>
<td>12%</td>
<td>—</td>
</tr>
<tr>
<td>Grade 3/4 Leukopenia</td>
<td>8%</td>
<td>18%</td>
<td>—</td>
</tr>
<tr>
<td>Peripheral Neuropathy (All Grades)</td>
<td>38%</td>
<td>53%</td>
<td>0.04</td>
</tr>
<tr>
<td>Grade ≥3 Peripheral Neuropathy</td>
<td>6%</td>
<td>16%</td>
<td>0.03</td>
</tr>
</tbody>
</table>


Author Conclusions

- The efficacy of bortezomib is similar by SC and IV administration in patients with relapsed MM.
- The PK-PD profiles of SC and IV bortezomib are similar (data not shown).
- SC administration of bortezomib appears to have an improved safety profile with respect to peripheral neuropathy compared to IV administration.
- SC administration has acceptable local tolerability (data not shown).

Investigator comment on subcutaneous versus intravenous administration route for bortezomib in multiple myeloma

This is definitely exciting as it makes it more convenient for the patients, who may not have to have an IV line placed for bortezomib infusions. Based on this study, the subcutaneous route of administration of bortezomib appears to be at least as effective, if not potentially even better than, the intravenous route. The data even show a lower rate of peripheral neuropathy and ≥Grade 3 adverse events.

This opens a new door for a more convenient treatment for patients with myeloma, many of whom have difficulties with mobility and access to the clinic. Even self-administration approaches could be explored without any compromise in tolerability. Hopefully this will be adopted as a standard approach as more information comes forward.

*Interview with Rafael Fonseca, MD, December 22, 2010*